Biotech Values

[DewDiligence]

Re: Non-ifn regimens for HCV

>are there any drugs seeking approval via a clinical program without IFN? Your answer at the time was no. Obviously there are the earliest possible signs that that is changing - but so far I've only seen one trial aimed at a no IFN treatment<

Roche will likely start a trial of ITMN191 + R7128 within the next six months. They may also test ITMN191 + R1626.

>As standalone agents how well do some of the candidates for a drug cocktail work?<

R7128 showed a mean 2.7-log reduction in viral load (with zero cases of viral breakthrough) after 14 days of monotherapy in patients with prior ifn failures.

p.s. IDX184 may be the best candidate of all for a non-ifn cocktail insofar as it appears to be synergistic (rather than merely additive) with ribavirin.